Drug Profile
BI 765063
Alternative Names: Anti-SIRPa mAb - OSE Therapeutics; Anti-SIRPa monoclonal antibody - OSE Therapeutics; BI-765063; Effi dem; OSE 172Latest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator Effimune
- Developer Boehringer Ingelheim; OSE Immunotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; SIRPA protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; Liver cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 08 Nov 2023 Boehringer Ingelheim terminates a phase I trial in Colorectal cancer (Combination therapy, First-line therapy, Neoadjuvant therapy) in USA (IV) due to company decision (NCT05446129)
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 14 Apr 2023 Updated efficacy and pharmacodynamics data from a phase I trial in Solid tumours presented at the114th Annual Meeting of the American Association for Cancer Research (AACR-2023) .